-
2
-
-
84958033425
-
The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system
-
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40:244–52.
-
(2016)
Am J Surg Pathol
, vol.40
, pp. 244-252
-
-
Epstein, J.I.1
Egevad, L.2
Amin, M.B.3
Delahunt, B.4
Srigley, J.R.5
Humphrey, P.A.6
-
3
-
-
58549118240
-
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
-
Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9–17.
-
(2009)
Cancer Treat Rev
, vol.35
, pp. 9-17
-
-
Shelley, M.D.1
Kumar, S.2
Wilt, T.3
Staffurth, J.4
Coles, B.5
Mason, M.D.6
-
4
-
-
84905993578
-
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study
-
Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014;32: 3705–15.
-
(2014)
J Clin Oncol
, vol.32
, pp. 3705-3715
-
-
Taplin, M.E.1
Montgomery, B.2
Logothetis, C.J.3
Bubley, G.J.4
Richie, J.P.5
Dalkin, B.L.6
-
5
-
-
84938350452
-
Combination cancer immunotherapy and new immunomodulatory targets
-
Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14:561–84.
-
(2015)
Nat Rev Drug Discov
, vol.14
, pp. 561-584
-
-
Mahoney, K.M.1
Rennert, P.D.2
Freeman, G.J.3
-
6
-
-
84937516588
-
A systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G
-
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015;68:267–79.
-
(2015)
Eur Urol
, vol.68
, pp. 267-279
-
-
Carosella, E.D.1
Ploussard, G.2
LeMaoult, J.3
Desgrandchamps, F.4
-
7
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
8
-
-
84939227614
-
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers
-
Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015;10:e0130142.
-
(2015)
PLoS One
, vol.10
-
-
Carbognin, L.1
Pilotto, S.2
Milella, M.3
Vaccaro, V.4
Brunelli, M.5
Calio, A.6
-
9
-
-
84904024273
-
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
-
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064–74.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5064-5074
-
-
Taube, J.M.1
Klein, A.2
Brahmer, J.R.3
Xu, H.4
Pan, X.5
Kim, J.H.6
-
10
-
-
84947031227
-
Paucity of PD-L1 expression in prostate cancer: Innate and adaptive immune resistance
-
Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis 2015;18:325–32.
-
(2015)
Prostate Cancer Prostatic Dis
, vol.18
, pp. 325-332
-
-
Martin, A.M.1
Nirschl, T.R.2
Nirschl, C.J.3
Francica, B.J.4
Kochel, C.M.5
Van Bokhoven, A.6
-
11
-
-
84946935007
-
Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: An exploratory analysis
-
Massari F, Ciccarese C, Calio A, Munari E, Cima L, Porcaro AB, et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Target Oncol 2016;11:345–51.
-
(2016)
Target Oncol
, vol.11
, pp. 345-351
-
-
Massari, F.1
Ciccarese, C.2
Calio, A.3
Munari, E.4
Cima, L.5
Porcaro, A.B.6
-
12
-
-
84967166401
-
The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer
-
Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 2016;22:1969–77.
-
(2016)
Clin Cancer Res
, vol.22
, pp. 1969-1977
-
-
Gevensleben, H.1
Dietrich, D.2
Golletz, C.3
Steiner, S.4
Jung, M.5
Thiesler, T.6
-
13
-
-
85017503544
-
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
-
Ness N, Andersen S, Khanehkenari MR, Nordbakken CV, Valkov A, Paulsen EE, et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget 2017;8:26789–801.
-
(2017)
Oncotarget
, vol.8
, pp. 26789-26801
-
-
Ness, N.1
Andersen, S.2
Khanehkenari, M.R.3
Nordbakken, C.V.4
Valkov, A.5
Paulsen, E.E.6
-
14
-
-
84960080350
-
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discor-dances: A potential issue for anti-PD-L1 therapeutic strategies
-
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discor-dances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016;27:147–53.
-
(2016)
Ann Oncol
, vol.27
, pp. 147-153
-
-
Ilie, M.1
Long-Mira, E.2
Bence, C.3
Butori, C.4
Lassalle, S.5
Bouhlel, L.6
-
15
-
-
84959577118
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
-
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.
-
(2016)
Lancet
, vol.387
, pp. 1909-1920
-
-
Rosenberg, J.E.1
Hoffman-Censits, J.2
Powles, T.3
Van Der Heijden, M.S.4
Balar, A.V.5
Necchi, A.6
-
16
-
-
84923078390
-
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
-
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–62.
-
(2014)
Nature
, vol.515
, pp. 558-562
-
-
Powles, T.1
Eder, J.P.2
Fine, G.D.3
Braiteh, F.S.4
Loriot, Y.5
Cruz, C.6
-
17
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–7.
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
Fine, G.D.4
Hamid, O.5
Gordon, M.S.6
-
18
-
-
84982267373
-
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
-
Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016;7:52810–17.
-
(2016)
Oncotarget
, vol.7
, pp. 52810-52817
-
-
Graff, J.N.1
Alumkal, J.J.2
Drake, C.G.3
Thomas, G.V.4
Redmond, W.L.5
Farhad, M.6
-
19
-
-
84921371152
-
PD-L1 is highly expressed in enzalutamide resistant prostate cancer
-
Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, et al. PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget 2015;6:234–42.
-
(2015)
Oncotarget
, vol.6
, pp. 234-242
-
-
Bishop, J.L.1
Sio, A.2
Angeles, A.3
Roberts, M.E.4
Azad, A.A.5
Chi, K.N.6
-
20
-
-
84964858970
-
Assessment of the PD-L1 status by immunohistochemistry: Challenges and perspectives for therapeutic strategies in lung cancer patients
-
Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 2016;468: 511–25.
-
(2016)
Virchows Arch
, vol.468
, pp. 511-525
-
-
Ilie, M.1
Hofman, V.2
Dietel, M.3
Soria, J.C.4
Hofman, P.5
-
21
-
-
84942867600
-
Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art?
-
Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015;10:985–9.
-
(2015)
J Thorac Oncol
, vol.10
, pp. 985-989
-
-
Kerr, K.M.1
Tsao, M.S.2
Nicholson, A.G.3
Yatabe, Y.4
Wistuba, I.I.5
Hirsch, F.R.6
-
22
-
-
70349485580
-
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+
-
Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009;69:1694–703.
-
(2009)
Prostate
, vol.69
, pp. 1694-1703
-
-
Sfanos, K.S.1
Bruno, T.C.2
Meeker, A.K.3
De Marzo, A.M.4
Isaacs, W.B.5
Drake, C.G.6
-
23
-
-
85020475365
-
The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the `immunoreactive' microenvironment of colorectal carcinoma
-
Prall F, Huhns M. The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the `immunoreactive' microenvironment of colorectal carcinoma. Histopathology 2017;71:366–74.
-
(2017)
Histopathology
, vol.71
, pp. 366-374
-
-
Prall, F.1
Huhns, M.2
-
24
-
-
84938984463
-
The prognostic landscape of genes and infiltrating immune cells across human cancers
-
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938–45.
-
(2015)
Nat Med
, vol.21
, pp. 938-945
-
-
Gentles, A.J.1
Newman, A.M.2
Liu, C.L.3
Bratman, S.V.4
Feng, W.5
Kim, D.6
-
25
-
-
20244380618
-
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
-
Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239–49.
-
(2005)
Cancer Cell
, vol.7
, pp. 239-249
-
-
Drake, C.G.1
Doody, A.D.2
Mihalyo, M.A.3
Huang, C.T.4
Kelleher, E.5
Ravi, S.6
-
26
-
-
77951937514
-
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses
-
Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol 2010;71:496–504.
-
(2010)
Hum Immunol
, vol.71
, pp. 496-504
-
-
Morse, M.D.1
McNeel, D.G.2
-
27
-
-
23444461765
-
Activation of thymic regeneration in mice and humans following androgen blockade
-
Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741–53.
-
(2005)
J Immunol
, vol.175
, pp. 2741-2753
-
-
Sutherland, J.S.1
Goldberg, G.L.2
Hammett, M.V.3
Uldrich, A.P.4
Berzins, S.P.5
Heng, T.S.6
-
28
-
-
33947399305
-
Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level
-
Radojevic K, Arsenovic-Ranin N, Kosec D, Pesic V, Pilipovic I, Perisic M, et al. Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level. J Endocrinol 2007;192:669–82.
-
(2007)
J Endocrinol
, vol.192
, pp. 669-682
-
-
Radojevic, K.1
Arsenovic-Ranin, N.2
Kosec, D.3
Pesic, V.4
Pilipovic, I.5
Perisic, M.6
-
29
-
-
68749087029
-
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
-
Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348:9–17.
-
(2009)
J Immunol Methods
, vol.348
, pp. 9-17
-
-
Gannon, P.O.1
Poisson, A.O.2
Delvoye, N.3
Lapointe, R.4
Mes-Masson, A.M.5
Saad, F.6
-
30
-
-
84860133344
-
Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells
-
Tang S, Moore ML, Grayson JM, Dubey P. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 2012;72:1975–85.
-
(2012)
Cancer Res
, vol.72
, pp. 1975-1985
-
-
Tang, S.1
Moore, M.L.2
Grayson, J.M.3
Dubey, P.4
-
31
-
-
84963589359
-
Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
-
Pu Y, Xu M, Liang Y, Yang K, Guo Y, Yang X, et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci Transl Med 2016;8:333ra47.
-
(2016)
Sci Transl Med
, vol.8
, pp. 333ra47
-
-
Pu, Y.1
Xu, M.2
Liang, Y.3
Yang, K.4
Guo, Y.5
Yang, X.6
-
32
-
-
84946195510
-
The molecular taxonomy of primary prostate cancer
-
Cancer Genome Atlas Research Network
-
Cancer Genome Atlas Research Network.The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011–25.
-
(2015)
Cell
, vol.163
, pp. 1011-1025
-
-
-
33
-
-
84978786133
-
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: Could it be predictive and/or prognostic in non-small cell lung cancer?
-
Mino-Kenudson M.Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med 2016;13:157–70.
-
(2016)
Cancer Biol Med
, vol.13
, pp. 157-170
-
-
Mino-Kenudson, M.1
-
34
-
-
33846118474
-
Loss of tumor suppressor PTEN function increases B7-H1 expression and immu-noresistance in glioma
-
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immu-noresistance in glioma. Nat Med 2007;13:84–8.
-
(2007)
Nat Med
, vol.13
, pp. 84-88
-
-
Parsa, A.T.1
Waldron, J.S.2
Panner, A.3
Crane, C.A.4
Parney, I.F.5
Barry, J.J.6
-
35
-
-
84969185739
-
Do African-American men need separate prostate cancer screening guidelines?
-
Shenoy D, Packianathan S, Chen AM, Vijayakumar S. Do African-American men need separate prostate cancer screening guidelines? BMC Urol 2016;16:19.
-
(2016)
BMC Urol
, vol.16
, pp. 19
-
-
Shenoy, D.1
Packianathan, S.2
Chen, A.M.3
Vijayakumar, S.4
-
36
-
-
84963576532
-
Mutational landscape of aggressive prostate tumors in African American Men
-
Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, et al. Mutational landscape of aggressive prostate tumors in African American Men. Cancer Res 2016;76:1860–8.
-
(2016)
Cancer Res
, vol.76
, pp. 1860-1868
-
-
Lindquist, K.J.1
Paris, P.L.2
Hoffmann, T.J.3
Cardin, N.J.4
Kazma, R.5
Mefford, J.A.6
|